Saturday 17 October 2026 Export TLRY’s income statement to Excel — free account

Tilray Brands, Inc.

TLRY Healthcare Drug Manufacturers Specialty & Generic

Tilray Brands, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $915.5 million, up 11.5% from fiscal 2025. In the quarter to August 2026, revenue grew 22.7%, EPS was flat, free cash flow fell 36.6% and total debt rose 43.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.04 0.17 −5.30%

Follow TLRY

Alert me

Market cap: $474.4M
P/E: 0.0×
Fwd P/E: −14.8×
Dividend yield: —
F-score: 3/9
Altman Z: −1.96
Beneish M: −2.01
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.07

Total sells 0.23

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	3	—	—
Sell	—	—	—	—	—	1	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 474.40

Revenue 963.10

Net Income (146.70)

Free Cash Flow (174.45)

Net Debt 129.95

Current Ratio 1.88

Debt/Equity 0.22

P/E ratio 0.00

Fwd P/E (14.80)

P/S ratio 0.42

P/B ratio 0.25

Past 5Y EPS Growth —

This Y EPS Growth 46.44%

Next Y EPS Growth 65.17%

Next Y revenue growth 20.38%

Next 5Y EPS Growth 63.05%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.26%

10-year low 10-year high

P/B against its own 10 years 4.32%

10-year low 10-year high

EV/Sales against its own 10 years 0.97%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	261	256	235	221
Receivables	102	121	189	191
Inventory	252	271	301	329
Other	—	—	—	—
	678	689	792	808

	2024	2025	2026	Q'26
Payables	242	235	318	335
ST’ Debt	16	15	18	75
Other	18	16	—	—
	299	280	358	431

Compound Annual Growth %

	10y	5y	3y
Sales	8.49%	7.82%	13.44%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	2.26%	(18.37%)	(21.65%)

Revenue $m

	Aug	Nov	Feb	May	Year
’26	257	—	—	—	—
’26	210	218	207	282	915
’25	200	211	186	225	821
’24	—	—	188	230	789
’23	177	194	—	—	627
’23	—	—	146	184	627
’22	153	144	—	—	628

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Aug	Nov	Feb	May	Year
’26	(17)	—	—	—	—
’26	(1)	(9)	(22)	(37)	(69)
’25	(35)	(41)	(6)	(13)	(95)
’24	—	—	(15)	31	(31)
’23	(16)	(30)	—	—	8
’23	—	—	(19)	44	8
’22	(46)	29	—	—	(177)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Aug	Nov	Feb	May	Year
’26	(27)	—	—	—	—
’26	(20)	(18)	(24)	(69)	(99)
’25	(42)	(46)	(20)	(40)	(121)
’24	—	—	(24)	28	(52)
’23	(24)	(36)	—	—	8
’23	—	—	(17)	33	(9)
’22	(48)	25	—	—	(177)

Fiscal quarters ending in the months shown.

EPS $

	Aug	Nov	Feb	May	Year
’26	(0.30)	—	—	—	—
’26	0.00	(0.41)	(0.24)	(0.43)	(1.09)
’25	(0.40)	(1.00)	(8.70)	(13.00)	(24.60)
’24	—	—	(1.20)	(0.40)	(3.30)
’23	(1.00)	(0.70)	—	—	(2.35)
’23	—	—	(19.00)	(1.77)	(23.50)
’22	(1.30)	(1.10)	—	—	(0.99)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	40.51	84.00	155.70	24.30	69.70	25.20	15.00	11.40	3.50	3.03	Analyst estimates 2027–2029 Powerpack
	High	188.62	3,000.00	1,060.00	229.50	670.00	90.80	35.90	29.70	23.20	10.13
People
People	Employees	330	688	1,646	1,030	2,100	1,800	1,600	2,650	2,842	3,595
	Revenue/emp, $m	0.06	0.06	0.10	0.20	0.00	0.00	0.00	0.30	0.29	0.25
Income, $m
Income, $m	Revenue	21	43	167	210	513	628	627	789	821	915
	Gross margin, %	55.39	33.10	(14.07)	11.71	17.14	0.26	8.53	28.31	29.29	28.45
	EBT	(8)	(72)	(330)	(277)	(345)	(441)	(1,450)	(249)	(2,302)	(88)
	EBT margin, %	(38.02)	(167.34)	(197.40)	(131.45)	(67.15)	(70.13)	(231.24)	(31.56)	(280.33)	(9.62)
	Net income	(8)	(68)	(321)	(271)	(367)	(477)	(1,453)	(222)	(2,181)	(105)
	Depreciation	2	6	26	30	68	155	130	141	144	76
Per share, $
Per share, $	Revenue	2.74	5.20	16.62	16.70	1.90	1.31	1.01	10.62	9.22	8.19
	Earnings	(1.04)	(8.16)	(31.97)	(21.51)	(1.36)	(0.99)	(2.35)	(3.30)	(24.60)	(1.09)
	Cash flow	(0.80)	(5.57)	(25.69)	(10.26)	(0.17)	(0.37)	0.01	(0.42)	(1.06)	(0.62)
	Capex	(1.52)	(6.47)	(7.17)	(3.33)	0.00	0.00	0.00	(0.28)	(0.29)	(0.26)
	Free cash flow	(2.32)	(12.05)	(32.86)	(13.59)	(0.17)	(0.37)	0.01	(0.70)	(1.36)	(0.88)
	Book value	(0.65)	23.81	28.40	29.66	16.54	9.14	5.37	46.36	16.73	14.26
	Shares, m	8	8	10	13	270	481	618	74	89	112
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	70.32	111.49	10.07	33.47	4.91	2.79	2.32	1.69	0.44	0.67
	P/B	0.00	29.63	5.89	31.76	0.72	0.38	0.48	0.39	0.25	0.39
	EV/Sales	71.08	109.97	12.30	33.90	5.53	3.05	2.66	1.83	0.52	0.83
	EV/FCF	(94.90)	(58.99)	(7.79)	(136.04)	(66.92)	(12.75)	(44.92)	(27.04)	(2.90)	(4.81)
Cash, $m
Cash, $m	Operating cash flow	(6)	(46)	(258)	(129)	(45)	(177)	8	(31)	(95)	(69)
	Capex	(11)	(54)	(72)	(42)	(39)	(34)	(21)	(21)	(26)	(29)
	Free cash flow	(17)	(100)	(330)	(171)	(45)	(177)	8	(52)	(121)	(99)
Balance, $m
Balance, $m	Working capital	(38)	528	167	166	483	524	340	379	408	434
	Total debt	18	429	434	311	939	624	590	364	315	376
	Net debt	16	(89)	337	121	451	208	141	104	58	142
	Shareholders’ equity	(5)	198	285	374	4,459	4,399	3,316	3,443	1,490	1,595
Returns, %
Returns, %	ROA	(27.86)	(19.06)	(41.36)	(20.20)	(6.10)	(8.75)	(33.37)	(5.68)	(69.46)	(5.52)
	ROIC	(43.25)	(33.14)	(30.53)	(25.40)	0.00	0.00	0.00	(3.08)	(92.17)	(2.27)
	ROE	672.03	(70.25)	(133.01)	(32.88)	(8.23)	(10.79)	(43.72)	(7.25)	(88.66)	(7.87)

Negative figures in brackets.

All 10 years →

Fiscal years to May 2026 · latest quarter Aug 2026 · fundamentals updated 13 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
IRWD Ironwood Pharmaceuticals, Inc.	$623.0M	4.4×	2.8×	+32.62% (above 0%: growing)	+106.67% (above 0%: growing)	+486.70% (above 0%: growing)	100.00%	70.16%	Compare
AQST Aquestive Therapeutics, Inc.	$509.6M	— (loss-making)	— (loss-making)	+38.15% (above 0%: growing)	n/m	−20.35% (below 0%: shrinking)	70.93%	(59.51%)	Compare
EVO Evotec AG	$504.4M	— (loss-making)	— (loss-making)	−12.98% (below 0%: shrinking)	n/m	−9,727.20% (below 0%: shrinking)	(1.00%)	(77.50%)	Compare
EOLS Evolus, Inc.	$500.0M	— (loss-making)	— (loss-making)	+21.18% (above 0%: growing)	n/m	+84.90% (above 0%: growing)	68.00%	(5.40%)	Compare
TLRY Tilray Brands, Inc.	$474.4M	— (loss-making)	— (loss-making)	+22.74% (above 0%: growing)	n/m	−36.60% (below 0%: shrinking)	30.14%	(9.35%)
KMDA Kamada Ltd.	$451.7M	20.4×	— (loss-making)	+22.72% (above 0%: growing)	+23.08% (above 0%: growing)	+165.71% (above 0%: growing)	40.91%	17.32%	Compare
TKNO Alpha Teknova, Inc.	$408.0M	— (loss-making)	— (loss-making)	+18.45% (above 0%: growing)	n/m	+74.18% (above 0%: growing)	40.09%	(23.72%)	Compare
EBS Emergent Biosolutions Inc.	$368.1M	— (loss-making)	— (loss-making)	+66.29% (above 0%: growing)	n/m	−47.68% (below 0%: shrinking)	58.56%	(53.39%)	Compare
CGC Canopy Growth Corporation	$311.2M	— (loss-making)	— (loss-making)	+12.41% (above 0%: growing)	n/m	−117.60% (below 0%: shrinking)	27.40%	(27.24%)	Compare
Median of peers	$475.9M	—	—	+21.95%	—	+26.92%	49.74%	(25.48%)

All 86 Drug Manufacturers Specialty & Generic stocks →